Physiologically‐Based Pharmacokinetic Model for Alectinib, Ruxolitinib, and Panobinostat in The Presence of Cancer, Renal Impairment, and Hepatic Impairment
2020 ◽
Vol 60
(8)
◽
pp. 999-1010
◽
2019 ◽
Vol 27
(3)
◽
pp. 107
◽
2020 ◽
Vol 109
(9)
◽
pp. 2909-2918